Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...

And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics ( VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

The ex-husband of a woman in France was handed a 20-year prison sentence on Thursdaay for drugging and raping her and ...

Merck has entered a $2 billion licensing deal with China's Hansoh Pharma for an oral weight-loss drug, positioning itself ...

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...